[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590991":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":30,"locations":36,"responsibleParty":58,"collaborators":29,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":29,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":29,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":29,"overallStatus":38,"whyStopped":29,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Cairo University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sphenopalatine block group","EXPERIMENTAL","Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.",[13],"Drug: Sphenopalatine block",{"label":15,"type":10,"description":16,"interventionNames":17},"BOTOX group","Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.",[18],"Drug: Botulinum Toxin Type A",[20,26],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Sphenopalatine block",[9],[25],"Lidocaine",{"type":21,"name":27,"description":16,"armGroupLabels":28,"otherNames":29},"Botulinum Toxin Type A",[15],null,[31],{"name":32,"role":33,"phone":34,"phoneExt":29,"email":35},"Mohamed E Abdel Fattah, MD","CONTACT","00201284475792","mohamed-elsaid@cu.edu.eg",[37],{"facility":5,"status":38,"city":39,"state":29,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Cairo","12613","Egypt","EG",{"type":44,"coordinates":45},"Point",[46,47],31.24967,30.06263,{"lat":47,"lon":46},[50,51,54,56],{"name":32,"role":33,"phone":34,"phoneExt":29,"email":35},{"name":52,"role":53,"phone":29,"phoneExt":29,"email":29},"Samuel F Samy, MD","PRINCIPAL_INVESTIGATOR",{"name":55,"role":53,"phone":29,"phoneExt":29,"email":29},"Amany M Abo Taleb, MD",{"name":57,"role":53,"phone":29,"phoneExt":29,"email":29},"Mohammed S ElSharkawy, MD",{"type":53,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Mohamed Elsaid Abdel Fattah","Lecturer of Anesthesia, Surgical ICU and Pain Management, Faculty of Medicine, National Cancer Institute, Cairo University, Egypt.","100590991","sphenopalatine-block-versus-botox-in-management-of-chronic-migraine-100590991",false,"NCT06974617","Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine","Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 and 65 years.\n* Both sexes.\n* Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta.\n\nExclusion Criteria:\n\n* Patients with medication over use headache.\n* Bleeding disorders.\n* Abnormal neurological examination.\n* History of allergy to local anesthetics or BOTOX.","ALL","18 Years","65 Years",{"count":72,"type":73},64,"ESTIMATED","INTERVENTIONAL",[76],"NA","This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.",[79,80,81],"Sphenopalatine Block","BOTOX","Chronic Migraine","2025-05-15",{"date":84,"type":85},"2025-05-16","ACTUAL",{"date":82,"type":85},{"date":88,"type":73},"2025-10-01",{"name":5,"class":6},1]